GLP-1 for PCOS and insulin resistance: what the evidence shows

What did @jazsofit actually say?

Honestly? Not much that's fact-checkable. The transcript submitted for this video is song lyrics, not health commentary. The words attributed to @jazsofit are from a rap track, not a GLP-1 testimonial. The caption, though, does make claims worth examining: that GLP-1 receptor agonists changed her life, and that fear-mongering around these medications is overblown, specifically in the context of PCOS and insulin resistance.

So we're fact-checking the caption and the implied claims it carries, because that's what 11,900 viewers are actually absorbing. The hashtags #pcos, #insulinresistance, and #glp1community signal that this post is presenting GLP-1 use as a solution for those specific conditions. That framing deserves scrutiny.

Does the science back this up?

Partially, yes. GLP-1 receptor agonists do show real promise for PCOS, particularly for patients whose PCOS is driven by insulin resistance. But the evidence is still maturing, and the FDA has not approved semaglutide or tirzepatide specifically for PCOS treatment.

A 2023 meta-analysis by Govinden et al. in Frontiers in Endocrinology found that GLP-1 receptor agonists improved menstrual regularity, reduced androgen levels, and lowered BMI in women with PCOS compared to placebo. A smaller RCT by Cena et al. (2021, Nutrients) found liraglutide improved metabolic markers in PCOS patients with obesity. These are real findings. They are not, however, proof that GLP-1 medications are a universal fix for PCOS. Many PCOS patients do not have significant insulin resistance, and the mechanism of benefit may not apply broadly across PCOS phenotypes.

The "stop being scared" framing also deserves pushback. Side effects including nausea, vomiting, gastroparesis, and rare but serious pancreatitis risk are real considerations, not internet hysteria.

What did they get wrong (or right)?

What she got right: there is a legitimate evidence base for GLP-1 use in insulin-resistant PCOS, and some of the fear around these medications is disproportionate to actual risk profiles in otherwise healthy patients. The lived-experience framing, "I'm so comfortable living in my body now," is a valid personal account and not a medical claim in itself.

What's missing or potentially misleading: describing GLP-1 as a life-changer for PCOS without acknowledging that response varies significantly by phenotype risks setting unrealistic expectations. A patient with lean PCOS or non-insulin-resistant PCOS may not see the same benefits. The caption also doesn't address the access problem. Brand-name semaglutide (Wegovy, Ozempic) costs over $900 per month without insurance, and compounded versions carry their own regulatory and consistency concerns that are not equivalent to FDA-approved formulations.

There's also no mention of the importance of clinical supervision. GLP-1 medications require monitoring, dose titration, and assessment of contraindications including personal or family history of medullary thyroid carcinoma.

What should you actually know?

GLP-1 receptor agonists are not approved by the FDA to treat PCOS. They are approved for type 2 diabetes management (semaglutide as Ozempic, liraglutide as Victoza) and chronic weight management (semaglutide as Wegovy, tirzepatide as Zepbound). Prescribing them for PCOS is off-label, which is legal and common in medicine but means you are relying on emerging rather than definitive evidence.

If you have PCOS with confirmed insulin resistance, the conversation with your provider about GLP-1 options is a reasonable one to have. If your PCOS is not insulin-driven, the calculus is different. Metformin still has a longer evidence track record for metabolic PCOS management, per the 2023 international PCOS guidelines (Teede et al., Human Reproduction).

Side effects are real. Roughly 40-50% of patients on semaglutide report gastrointestinal symptoms in the first weeks of use, per the STEP trials (Wilding et al., 2021, NEJM). Most resolve with time and proper titration, but they are not nothing.

• GLP-1 medications are not FDA-approved for PCOS specifically.
• Benefit in PCOS appears strongest in patients with documented insulin resistance.
• Compounded GLP-1 products are not the same as brand-name FDA-approved medications.
• Side effects are common early in treatment and require clinical supervision to manage safely.